These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12162701)

  • 1. Advantages of antisense drugs for the treatment of oral diseases.
    Nedbal W; Teichmann B
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):183-91. PubMed ID: 12162701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases.
    Tomita N; Morishita R
    Curr Pharm Des; 2004; 10(7):797-803. PubMed ID: 15032704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
    Crooke RM; Graham MJ
    Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural modifications of antisense oligonucleotides.
    Urban E; Noe CR
    Farmaco; 2003 Mar; 58(3):243-58. PubMed ID: 12620420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concept and application of antisense oligonucleotides.
    Yacyshyn BR; Crooke ST
    Dis Colon Rectum; 2001 Sep; 44(9):1241-3. PubMed ID: 11584192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does antisense make sense in dermatology?
    van Erp PE; Wingens M
    Acta Derm Venereol; 2001; 81(6):385-91. PubMed ID: 11859937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease.
    Haller H; Maasch C; Dragun D; Wellner M; von Janta-Lipinski M; Luft FC
    Kidney Int; 1998 Jun; 53(6):1550-8. PubMed ID: 9607185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides.
    Mehta RC; Stecker KK; Cooper SR; Templin MV; Tsai YJ; Condon TP; Bennett CF; Hardee GE
    J Invest Dermatol; 2000 Nov; 115(5):805-12. PubMed ID: 11069617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical pharmacology of antisense oligonucleotides.
    Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
    Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
    Henry SP; Marcusson EG; Vincent TM; Dean NM
    Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense therapeutics: is it as simple as complementary base recognition?
    Agrawal S; Kandimalla ER
    Mol Med Today; 2000 Feb; 6(2):72-81. PubMed ID: 10652480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
    Golden T; Dean NM; Honkanen RE
    Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.